DBI Stock Overview
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Deutsche Biotech Innovativ AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.05 |
| 52 Week High | €34.40 |
| 52 Week Low | €5.00 |
| Beta | 0.34 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -79.80% |
| 3 Year Change | -92.89% |
| 5 Year Change | -92.84% |
| Change since IPO | -34.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -1.9% |
| 1Y | -79.8% | -15.0% | 1.1% |
Return vs Industry: DBI underperformed the German Biotechs industry which returned -22.1% over the past year.
Return vs Market: DBI underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| DBI volatility | |
|---|---|
| DBI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DBI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DBI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Bernd Wegener | www.dbi-ag.de |
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.
Deutsche Biotech Innovativ AG Fundamentals Summary
| DBI fundamental statistics | |
|---|---|
| Market cap | €4.55m |
| Earnings (TTM) | -€236.44k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-19.2x
P/E RatioIs DBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBI income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €236.44k |
| Earnings | -€236.44k |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DBI perform over the long term?
See historical performance and comparison